ESR1 and breast carcinoma: However, an increasing number of the clinical epidemiological investigations show that ERα-positive primary breast cancer patients have an increased frequency of ESR1 mutations in metastatic ERα+ breast cancer tissues and even ERα-negative metastatic relapse after receiving endocrine therapy1, 7.